超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國(guó)Alexion Pharmaceuticals
Alexion制藥公司是一家生物制藥企業(yè)，致力于為罹患重癥致命疾病的患者開(kāi)發(fā)生產(chǎn)救命藥物。Alexion公司從事治療藥物的探索、開(kāi)發(fā)和推廣，這些藥物用于治療種類廣泛的嚴(yán)重疾病，包括血液系統(tǒng)和腎臟疾病、移植、癌癥和自身免疫疾病。Soliris是Alexion公司首個(gè)上市的藥物。Alexion公司正在評(píng)估Soliris治療其他適應(yīng)證的可能性、以及依庫(kù)珠單抗其他劑型治療附加臨床適應(yīng)證的可能性，其他處于早期開(kāi)發(fā)階段的抗體備選產(chǎn)品也正在開(kāi)發(fā)中。

Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body's immune response and can destroy healthy tissue in certain patients.

Alexion discovered and developed Soliris? (eculizumab), a first-in-class terminal complement inhibitor approved in the United States, European Union, Canada and Australia as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.